New systemic treatments for psoriasis : etanercept, infliximab, adalimumab, efalizumab and alefacept
The chronic skin disease psoriasis frequently requires long-term systemic treatment with agents that suppresses the immune system with little specificity, which can lead to systemic side effects. Today, using recombinant techniques, it is possible to produce modified proteins, the so-called biologicals, that target specific molecules in the inflammatory process. For the biologicals etanercept, infliximab, adalimumab, efalizumab and alefacept, the clinical efficacy expressed in the rates of partial remission (75% reduction in skin lesions) in patients with plaque psoriasis range from 12 to 88%, compared with 22 to 87% for existing systemic therapies for psoriasis. The side effects of biologicals are usually mild to moderate, but can sometimes be severe. The biologicals should be prescribed with caution, given that they have been on the market for a relatively short period, and because all forms of immune suppression carry an increased risk of oncologic degeneration. The guideline of the Dutch Society of Dermatology and Venereology states that the use of a biological may be considered when a patient cannot tolerate or is unresponsive to conventional systemic therapy, or has an increased risk of adverse events. Biologicals increase the number of options for treatment-resistant plaque psoriasis, which allows therapy to be tailored to the individual patient.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2006 |
|---|---|
| Erschienen: |
2006 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:150 |
|---|---|
| Enthalten in: |
Nederlands tijdschrift voor geneeskunde - 150(2006), 19 vom: 13. Mai, Seite 1065-70 |
| Sprache: |
Niederländisch |
|---|
| Weiterer Titel: |
Nieuwe systemische behandelingen bij psoriasis: etanercept, infliximab, adalimumab, efalizumab en alefacept |
|---|
| Beteiligte Personen: |
Bos, W E M [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 22.06.2006 Date Revised 01.12.2018 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM163125163 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM163125163 | ||
| 003 | DE-627 | ||
| 005 | 20231223095700.0 | ||
| 007 | tu | ||
| 008 | 231223s2006 xx ||||| 00| ||dut c | ||
| 028 | 5 | 2 | |a pubmed24n0544.xml |
| 035 | |a (DE-627)NLM163125163 | ||
| 035 | |a (NLM)16733982 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a dut | ||
| 100 | 1 | |a Bos, W E M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New systemic treatments for psoriasis |b etanercept, infliximab, adalimumab, efalizumab and alefacept |
| 246 | 3 | 3 | |a Nieuwe systemische behandelingen bij psoriasis: etanercept, infliximab, adalimumab, efalizumab en alefacept |
| 264 | 1 | |c 2006 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 22.06.2006 | ||
| 500 | |a Date Revised 01.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The chronic skin disease psoriasis frequently requires long-term systemic treatment with agents that suppresses the immune system with little specificity, which can lead to systemic side effects. Today, using recombinant techniques, it is possible to produce modified proteins, the so-called biologicals, that target specific molecules in the inflammatory process. For the biologicals etanercept, infliximab, adalimumab, efalizumab and alefacept, the clinical efficacy expressed in the rates of partial remission (75% reduction in skin lesions) in patients with plaque psoriasis range from 12 to 88%, compared with 22 to 87% for existing systemic therapies for psoriasis. The side effects of biologicals are usually mild to moderate, but can sometimes be severe. The biologicals should be prescribed with caution, given that they have been on the market for a relatively short period, and because all forms of immune suppression carry an increased risk of oncologic degeneration. The guideline of the Dutch Society of Dermatology and Venereology states that the use of a biological may be considered when a patient cannot tolerate or is unresponsive to conventional systemic therapy, or has an increased risk of adverse events. Biologicals increase the number of options for treatment-resistant plaque psoriasis, which allows therapy to be tailored to the individual patient | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Dermatologic Agents |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Receptors, Tumor Necrosis Factor |2 NLM | |
| 650 | 7 | |a Recombinant Fusion Proteins |2 NLM | |
| 650 | 7 | |a Infliximab |2 NLM | |
| 650 | 7 | |a B72HH48FLU |2 NLM | |
| 650 | 7 | |a Alefacept |2 NLM | |
| 650 | 7 | |a ELK3V90G6C |2 NLM | |
| 650 | 7 | |a Adalimumab |2 NLM | |
| 650 | 7 | |a FYS6T7F842 |2 NLM | |
| 650 | 7 | |a Etanercept |2 NLM | |
| 650 | 7 | |a OP401G7OJC |2 NLM | |
| 650 | 7 | |a efalizumab |2 NLM | |
| 650 | 7 | |a XX2MN88N5D |2 NLM | |
| 700 | 1 | |a Thio, H B |e verfasserin |4 aut | |
| 700 | 1 | |a Neumann, H A M |e verfasserin |4 aut | |
| 700 | 1 | |a van der Fits, L |e verfasserin |4 aut | |
| 700 | 1 | |a Prens, E P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nederlands tijdschrift voor geneeskunde |d 1946 |g 150(2006), 19 vom: 13. Mai, Seite 1065-70 |w (DE-627)NLM000034231 |x 1876-8784 |7 nnns |
| 773 | 1 | 8 | |g volume:150 |g year:2006 |g number:19 |g day:13 |g month:05 |g pages:1065-70 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 150 |j 2006 |e 19 |b 13 |c 05 |h 1065-70 | ||